2-Isopropyl-cyclopentanol | 56470-87-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Isopropyl-cyclopentanol
• 英文别名: 2-Isopropyl-cyclopentanol-(1)；2-iso-propyl-1-cyclopentanol；2-Isopropylcyclopentan-1-ol；2-propan-2-ylcyclopentan-1-ol
• CAS: 56470-87-2
• 化学式: C₈H₁₆O
• 分子量: 128.214
• InChiKey: UNGWJJDVLCVVGB-UHFFFAOYSA-N

物化性质

• 沸点：
  181.0±8.0 °C(Predicted)
• 密度：
  0.930±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Isopropyl-cyclopentanol 在 aluminum oxide 、 N,O-双三甲硅基乙酰胺 、 氢气 、 三乙酰氧基硼氢化钠 、 溶剂黄146 、 pyridinium chlorochromate 作用下， 以 甲醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 102.5h， 生成
  参考文献：
  名称：

  The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist

  摘要：

  The optimisation of two series of 4-hydroxybenzothiazolone derived β2-adrenoceptor agonists, bearing α-substituted cyclopentyl and β-phenethyl amino-substituents, as inhaled long-acting bronchodilators is described. Analogues were selected for synthesis using a lipophilicity based hypothesis to achieve the targeted rapid onset of action in combination with a long duration of action. The profiling of the two series led to identification of the α-substituted cyclopentyl analogue 2 as the optimal compound with a comparable profile to the inhaled once-daily long-acting β2-adrenoceptor agonist indacaterol. On the basis of these data 2 was promoted as the backup development candidate to indacaterol from the Novartis LABA project.

  DOI：

  10.1016/j.bmcl.2014.06.014

文献信息

• 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20200108075A1

  公开（公告）日：2020-04-09

  3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.

  公式（I）的3-羰基氨基异喹啉化合物及其变体，以及它们作为HPK1（造血激酶1）抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫应答方面是有用的。还描述了抑制HPK1的方法，治疗HPK1依赖性疾病的方法，增强免疫应答的方法，以及制备3-羰基氨基异喹啉化合物的方法。
• TYK2 INHIBITORS AND USES THEREOF
  申请人：Nimbus Lakshmi, Inc.

  公开号：US20200131201A1

  公开（公告）日：2020-04-30

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用它们来抑制TYK2并治疗TYK2介导的疾病的方法。
• POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1
  申请人：Vanderbilt University

  公开号：US20200131180A1

  公开（公告）日：2020-04-30

  Described are positive allosteric modulators of muscarinic acetylcholine receptor M 1 (mAChR M 1 ), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.

  描述了甲型乙酰胆碱受体M1（mAChR M1）的正向变构调节剂，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗神经系统疾病、精神疾病或二者的方法。
• FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS
  申请人：HANDOK INC.

  公开号：US20160168156A1

  公开（公告）日：2016-06-16

  The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is —CH═CR 3 C(O)NR 4 R 5 , —C≡CC(O)NR 4 R 5 , or

  该披露提供了由化学式I或其药用可接受的盐、溶剂化合物、多型体、酯、互变异构体或前药表示的新型化合物。这些化合物可用作Trk的抑制剂，并且在治疗疼痛、癌症、炎症、神经退行性疾病和某些传染病方面是有用的。 在化合物I的某些化合物中，Q为—CH═CR3C(O)NR4R5，—C≡CC(O)NR4R5，或...
• 4-Azaindole Derivatives
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20150094328A1

  公开（公告）日：2015-04-02

  4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

  4-氮杂吲哚衍生物是肌胆碱受体（mAChR）M1的调节剂，可能对预防或疾病修饰或症状性治疗与神经系统疾病如阿尔茨海默病（AD）或带有Lewy小体的痴呆症相关的认知缺陷有效，并且包括4-氮杂吲哚衍生物作为活性成分的药物组合物。